Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 12.82% is 88% below its 5-year average of 111.38%, near the low end of its 5-year range (0.00%–1082.51%).
As of the fiscal period ended Wednesday, December 31, 2025. 15.08% above its 12-month average of 11.14%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2025-12-31): 12.82%.
DEBT TO ASSETS RATIO
12.82%
DEBT TO ASSETS RATIO AVG TTM
11.14%
DEBT TO ASSETS RATIO AVG 3Y
4.49%
DEBT TO ASSETS RATIO AVG 5Y
111.38%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+15.08%
CURRENT VS 3Y AVG
+185.21%
CURRENT VS 5Y AVG
-88.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+14143.89%
vs the sector median at left
Regencell Bioscience Holdings Limited
Market Cap
$3.64B
Debt to Assets Ratio
12.82%
TTM Avg
11.14%
3Y Avg
4.49%
5Y Avg
111.38%
Market Cap
$3.57B
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.54B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.52B
Debt to Assets Ratio
0.67%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.48B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.44B
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.38B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regencell Bioscience Holdings Limited (RGC) | $3.64B | 12.82% | 11.14% | 4.49% | 111.38% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | 0.03% | N/A | N/A | N/A |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 0.03% | N/A | N/A | N/A |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | 0.00% | N/A | N/A | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | 0.67% | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | 0.02% | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.47B | 0.91% | N/A | N/A | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | 0.06% | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 0.04% | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 0.04% | N/A | N/A | N/A |
Debt/Assets
12.8%
Debt/Equity
0.32
Current Ratio
1.42
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2025-12-31 | 12.82% |
| 2025-06-30 | 9.46% |
| 2024-12-29 | 0.00% |
| 2024-06-30 | 1.02% |
| 2023-12-30 | 0.00% |
| 2023-06-30 | 3.67% |
| 2022-12-30 | 0.00% |
| 2022-06-30 | 4.28% |
| 2021-12-30 | 0.01% |
| 2021-06-30 | 1082.51% |
| 2020-12-30 | 590.13% |
| 2020-06-30 | 597.24% |
